- News article -

Customer success-story: Optomed secured 1,97 M€ EU funding for Smartscope-X – affordable, accessible and automatic screening for diabetic retinopathy

12 Oct 2017

In May, the Finnish medical technology company Optomed was granted 1,97 M€ from Horizon 2020 SME Phase 2 instrument under the topic Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well. The funding will help Optomed make their product Smartscope-X the leading solution for diabetic retinopathy screening, supporting the company’s vision to provide affordable eye screenings to everyone.

Diabetic retinopathy is the most frequent cause of preventable blindness in working-aged adults, affecting people with all types of diabetes. Visual impairment and blindness caused by diabetic retinopathy can be prevented through early and effective screening. Currently, screening is costly, time-consuming and needs to be done by an ophthalmologist. Optomed’s solution will allow patients to do the screenings automatically and get the diagnosis in real-time.

Optomed’s fully automated diabetic retinopathy screening solution consists of three main components: a low-cost handheld camera, an automated screening algorithm and a cloud service for eyeground images. As a low-cost and portable solution, Smartscope-X can also provide access to screening for example in developing countries.

Spinverse supported Optomed in project preparation, including help in defining the scope, matching the call and assisting in writing the proposal. After a positive decision from the EU Commission in May 2017, Spinverse supported Optomed in the project negotiation phase.

“The cooperation with Spinverse worked well. The applicant always has the main responsibility during the application process, but the support from Spinverse and their expertise on the application process helped us achieve the desired outcome,” says Seppo Kopsala, CEO of Optomed.

The project officially began in August. Currently, Optomed is working on product development related to the integration between the camera and the software as well as choosing subcontractors for the server solution. Next steps towards the commercialization of Smartscope-X include several clinical tests and commercial pilots in target countries during 2018–2019.

What can you achieve with EU funding? See how we have helped companies create success stories and  contact us to discuss your options.

Photo credit: Optomed

- News -

Relevant posts

CTO Forum CTO of the Year CTO Survey

Cross-industry CTO Forum brings together Finnish technology leaders on 16th February

26 Jan 2021

The annual CTO Forum co-organised by Business Finland, Technology Industries of Finland and Spinverse is app...

Client News EU funding health technology

Project STARDUST aims to bring a new and revolutionary treatment approach for Parkinson’s patients

8 Jan 2021

Spinverse is one of the nine partners in the STARDUST project, launched in 2017, to create a miniaturised ne...

5G LuxTurrim5G

Smart Urban Furniture showcase offers a sneak peek into the future of cities

5 Jan 2021

In close collaboration with several LuxTurrim5G partners, the Aalto Design Factory (ADF) team has developed ...

CTO Forum CTO of the Year

Nominate your candidate for CTO of the Year 2021 and Innovation Professor of the Year 2021!

16 Dec 2020

Have you worked with an exceptional CTO in Finland? Would you also like to highlight an innovative professor...

health technology Our People CleverHealth Network

Talking about the future of health technologies with Heli Teerenhovi

14 Dec 2020

Heli Teerenhovi joined Spinverse as Senior Manager less than two months ago and has already familiarised her...

Client News digital healthcare H2020

Spinverse helped AICCELERATE get 10 M€ funding – project aims to develop AI solutions to improve hospital processes and patient care pathways

14 Dec 2020

The European Commission recently funded AICCELERATE, a multiparty project aiming to develop AI solutions to ...